Optinose gets FDA nod for Xhance in chronic rhinosinusitis without nasal polyps
Xhance is a drug-device combination product that utilises the Exhalation Delivery System engineered to administer a topical steroid…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Mar 24
Xhance is a drug-device combination product that utilises the Exhalation Delivery System engineered to administer a topical steroid…
18 Mar 24
Nestlé achieved a net reduction of 13.5% of its greenhouse gas (GHG) emissions in 2023 compared to its…
18 Mar 24
Ansys offers CPG giant a new approach to packaging development.
18 Mar 24
The brand invites kids nationwide to unleash their creativity; announces search for first-ever Dunkables Head of Imagination
18 Mar 24
Plastic- and aluminum-free coffee pods and visionary new brewer will lead the future of home coffee brewing
18 Mar 24
For years, Symrise has been systematically reducing its direct greenhouse gas emissions as well as those in its…
18 Mar 24
Employees from Knoxville and Nashville facilities recognized with personalized semi-trucks at celebratory event attended by leadership including PepsiCo Beverages North America CEO,…
18 Mar 24
To give fans even more ways to enjoy KD, Canada’s original Mac n’ Cheese is also debuting its…
15 Mar 24
AstraZeneca said that the acquisition will further expand the pipeline of Alexion, AstraZeneca Rare Disease, beyond complement inhibition,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Mar 24
The accelerated approval was based on the findings from the ongoing Phase 3 MAESTRO-NASH trial in which Rezdiffra…